Chi­nese med­i­cine play­er Tasly con­sid­ers Hong Kong IPO for its biotech arm: re­port

The biotech arm of a high-pro­file tra­di­tion­al Chi­nese med­i­cine mak­er is re­port­ed­ly plan­ning a $1 bil­lion dol­lar IPO — ex­act­ly the kind of mon­ey reg­u­la­tors want­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER